Related Experiment Video
Updated: Feb 6, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Prostate Cancer Radiotherapy: An Evolving Paradigm.
Charles N Catton1, Himu Lukka1, Jarad Martin1
1Charles N. Catton, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON, Canada; Himu Lukka, Juravinsiki Regional Cancer Centre and McMaster University, Hamilton, ON, Canada; and Jarad Martin, Calvary Mater Hospital and University of Newcastle, Newcastle, New South Wales, Australia.
This case study discusses radiotherapy options for a 69-year-old man diagnosed with Gleason score 3+4 prostate cancer. It highlights diagnostic and management challenges for localized prostate adenocarcinoma.
Area of Science:
- Oncology
- Urology
- Radiation Oncology
Background:
- A 69-year-old male presented with rising prostate-specific antigen (PSA) levels over 7 years.
- Biopsy revealed Gleason score 3+4 (grade group 2) adenocarcinoma of the prostate with bilateral involvement.
Purpose of the Study:
- To provide a clinical context for applying key study results to patient management.
- To discuss diagnostic and management challenges in prostate cancer.
- To explore radiotherapy as a treatment option for localized prostate adenocarcinoma.
Main Methods:
- Case presentation of a patient with newly diagnosed prostate cancer.
- Review of relevant medical literature on prostate cancer diagnosis and treatment.
- Evaluation of staging investigations including CT and bone scan.
Main Results:
- The patient had localized, intermediate-risk prostate cancer (Gleason 3+4, grade group 2).
- Staging scans showed no evidence of metastatic disease.
- The patient was considering radiotherapy after discussing surgical options.
Conclusions:
- Radiotherapy is a viable treatment option for localized prostate cancer.
- Individualized management approaches are crucial for prostate cancer patients.
- Understanding clinical context aids in applying research findings to practice.
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

